Healthcare & Life Sciences
Memo Therapeutics AG
Switzerlandmemo-therapeutics.com/home.html
acquiredacquired
acquired
Stage
8
Investors
About
Memo Therapeutics AG is a biotech company developing therapeutic antibodies derived from human immune responses; its lead program potravitug is in Phase II for treating BK polyomavirus infection in kidney transplant recipients. The company also uses its proprietary DROPZYLLA technology to mine antibody repertoires for additional antiviral and oncology antibody candidates.
Explore Memo Therapeutics AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.